Abstract Body

An effective strategy to achieve antiretroviral therapy (ART)-free remission in HIV+ individuals will likely require active and passive approaches. We optimized CD4-based Chimeric Antigen Receptor (CD4CAR) molecules to actively target infected cells, and combined with CCR5 editing to passively protect CD4CAR T cells against infection. This approach was modeled in nonhuman primates (NHPs) infected with simian/human immunodeficiency virus (SHIV) and suppressed long-term on ART. Our goal was to quantify the impact of NHP deltaCCR5 CD4CAR T cells on viral rebound following analytical treatment interruption (ATI).

Rhesus macaques (n = 4) were infected with SHIV, and suppressed by ART for at least 1 year prior to intervention. Autologous T cells were edited with NHP CCR5 CRISPR ribonucleoproteins, then modified with lentiviral vectors expressing HIV/SHIV-specific CD4CAR. CAR T cell products were infused without a conditioning regimen. Transplanted animals received a single dose of cell-associated viral envelope antigen to boost the persistence of these cells in vivo. Flow- and PCR-based assays were used to characterize the T cell infusion product and the persistence of these cells in blood and tissues. Plasma viral load was monitored weekly before and after T cell infusion and ATI.

Adjustments to the manufacturing protocol augmented the ratio of CD4 to CD8 CAR T cells, increasing the persistence of CAR+ CD4 lineages in vivo. Infusion of cell-based antigen was well tolerated and led to significant increases in the percentage of CAR+ T cells in peripheral blood. Following ART withdrawal, viral rebound was delayed in all animals; one remains undetectable at 53 days post-ATI.

Previous studies in patients and NHPs demonstrated low-level persistence of virus-specific CAR T cells in vivo, relative to CAR T cells for cancer. To our knowledge, ours is the first study to boost virus-specific CAR T cells in infected, suppressed hosts, and to delay/control post-ATI viral rebound via CAR T cell therapy. Due to the lack of a cytotoxic conditioning regimen, the safety profile of our approach is highly favorable. Our data reinforces the promise of deltaCCR5 CD4CAR T cell therapies for viral reservoir reduction in HIV+ individuals, including a Phase I clinical trial underway at the University of Pennsylvania (NCT03617198).